Statins Boost α-Secretase, but Not Through Cholesterol
In efforts to interfere with Aβ peptide production, most of the attention has been lavished on the β- and γ-secretase enzymes...
ALL NEWS
5723 RESULTS
Sort By:
- Most Recent
- Most Commented
Field Loses Chad Dickey, 40, to Cancer
Friends and colleagues grapple with the loss of this young investigator.
Merck Axes Verubecestat for Prodromal AD, Researchers Say ‘Go Earlier’
The Phase 3 APECS trial of Merck’s flagship BACE inhibitor ends prematurely following an interim safety analysis.
LOAD of Data Place Vascular Malfunction as Earliest Event in Alzheimer’s
Vascular troubles preceded amyloid deposition and other disease markers in a new Alzheimer’s progression model based on ADNI data.
Looking outside the Brain for Early Signs of AD
The use of gene expression profiling to characterize Alzheimer disease pathology has, unsurprisingly, focused on...
Cholinesterase Inhibitors Not What They're Cracked Up To Be?
The results of the AD2000 study of donepezil (Aricept) in Alzheimer's—published in the June 26 Lancet—made a big splash in the media pond. While confirming previous...
Dementia à la Mold? Fungi May Lurk in Alzheimer’s Brains
Fungal cells cropped up in multiple brain regions of all AD brains examined, but how they got there and what they are doing remains mysterious.
Do APP Knock-ins Call Overexpression Models of AD into Question?
P25 overexpression in APP transgenic mice is one of perhaps many artifacts of APP overexpression, APP, researchers charge. Do APP/PS1 transgenic mouse phenotypes need re-evaluation?
Robert D. Terry, 93, Co-Founder of U.S. Alzheimer’s Research
A veteran of the Battle of the Bulge, Terry trained legions of neuropathologists at Einstein and UCSD. He described paired helical filaments and linked synapse loss to cognitive decline.
Chris Dobson, Master of Protein Folding Research, Dies at 69
A chemist at the University of Cambridge, Dobson developed equations that described the kinetics of protein aggregation in diseases such as Alzheimer’s.
Topline Result for First DIAN-TU Clinical Trial: Negative on Primary
DIAN, Roche, Lilly disclose that neither gantenerumab nor solanezumab slowed cognitive decline in the first-pass comparison of drug and placebo groups. Analyses are ongoing; dose may have been too low.
Closing in on a Blood Test for Alzheimer’s?
A Japanese company enters the arena with a plasma Aβ test that rivals CSF for detecting brain amyloid.
Could Contaminated Scalpels Seed Amyloidosis?
A panel of experts concludes the evidence for this scary prospect is weak, but recommends neurosurgeons use separate neurosurgical instruments for young and old patients. The experts called for further studies.
Herpes Triggers Amyloid—Could This Virus Fuel Alzheimer’s?
Herpes viruses that are commonly found in human brain promote rapid Aβ fibrillization and deposition in AD model systems.
FDA Invites Comment on Drug Testing Guidance for Early AD
Scientists have turned their attention toward testing therapies in early-stage patients who have underlying brain pathology but little to no functional impairment...
Current Filters
- Date Range : All x